2 active not recruiting, 1 enrolling by invitation. 2 Phase 3, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Enrolling by invitation 1 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Gotistobart: new trials by email Literature Review of Gotistobart trials Research Report on Gotistobart
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gotistobart Long Term Extension (LTE) Study Gotistobart - Advanced Solid Tumor | Phase 3 | Enrolling by invitation | OncoC4, Inc. | 20 | 2026-07-28 | 2026-08-24 |
| ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | OncoC4, Inc. | 148 | 2023-12-11 | 2026-05-22 |
| ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors Gotistobart, Docetaxel - Non Small Cell Lung Cancer | Phase 3 | Active not recruiting | OncoC4, Inc. | 630 | 2023-06-28 | 2026-08-13 |
Carcinoma, Non-Small-Cell Lung (1)
OncoC4, Inc. (3)
United States (3) · Australia (1) · Belgium (1) · Canada (1) · China (1) · Germany (1) · Italy (1) · Netherlands (1) · South Korea (1) · Spain (1) · Turkey (Türkiye) (1) · United Kingdom (1)
David Wise, MD (1) · Kai He, MD, PhD (1) · Mark Socinski, MD (1) · Mark Stein, MD (1) · Tianhong Li, MD, PhD (1)
2023 (1)